CONCLUSIONS
atherosclerosis
ASYMPTOMATIC HYPERURICEMIA, ATHEROSCLEROSIS, OXIDATIVE STRESS, CAROTID ARTERY ATHEROSCLEROSIS
The current subanalysis of the PRIZE study may indicate a possibility that febuxostat, a selective XO inhibitor, reduces the MDA‐LDL/LDL‐C ratio, a potential marker of atherosclerosis and oxidative stress, in patients with asymptomatic hyperuricemia and carotid artery atherosclerosis. Nevertheless, this subanalysis is still subject to the challenges with the number of cases, the fact that the dose of febuxostat had not been increased, the heterogeneity of the involved patients, and the effects of drugs other than febuxostat and nonpharmacological treatments on UA and MDA‐LDL levels during the observation period. Further studies are required to validate our findings and elucidate the clinical antioxidant effect of febuxostat while considering those factors.